Aldi urgently pulls popular food product from shelves after glass contamination fears
All packets of the Urban Eats Japanese Style Vegetable Gyoza 750g, which are available for purchase at Aldi stores, have been recalled as they may contain glass.
The vegetable gyoza features a best-before date of March 27, 2027 and was available for purchase in Aldi stores in NSW, ACT, Victoria, Queensland, South Australia, and Western Australia.
Customers have been warned to not eat the food product as it may contain pieces of glass.
'Food products containing glass may cause illness/ injury if consumed,' a recall statement read.
They can return the products at the Aldi store at which they were purchased, where customers will receive a full refund.
'Any consumers concerned about their health should seek medical advice,' the statement read.
Those seeking further information should contact the Aldi Stores Food Recall Hotline on 1800 709 993.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
10 hours ago
- ABC News
Midwives express remorse after home birth and Victorian baby's death
Two midwives have told a coronial inquest about their regrets after a baby died in hospital following a home birth in 2022. The infant, who can only be known as Baby R, died in August 2022 of perinatal hypoxia, six days after an emergency caesarean at Bendigo Health. The inquest, held in the Coroners Court of Victoria this week, heard two private midwives present during the home birth of Baby R conceded their care was inadequate when complications arose, and that a transfer to the hospital should have happened sooner. The Melbourne court heard Baby R's mother, a former midwife herself, wanted a "natural" vaginal home birth after a traumatic first birth in 2019, which resulted in an emergency c-section after her baby was born macrosomic (large). The inquest heard on Thursday that under Australian midwifery guidelines, Baby R's mother was not considered suitable for a home birth. Earlier this week, an obstetrician at Bendigo Health said she held concerns at the time that the two private midwives were practising "outside national midwifery guidelines". Elizabeth Murphy was Baby R's mother's primary midwife while Marie-Louise Lapeyre, the only other private midwife in the region, was also present to assist in the birth. The women were experienced home birth midwives and had worked together frequently. The inquest heard doctors Andrew Woods and Helen Cooke suggested both midwives should have discussed a transfer to hospital with Baby R's mother about four hours earlier than they did. Ms Lapeyre broke down in court as she called it a "deep regret" and that "extreme tiredness" could have impaired her decision-making during the birth. Both women had come straight from other births and had not slept. The inquest heard Baby R's mother thought she would be on her way to hospital when she passed meconium liquor, which could indicate a baby in distress. Instead, Ms Lapeyre told her they would monitor the baby more closely. "I should've given Baby R's mother a choice and I didn't, and that goes against everything I stand for as a midwife," Ms Lapeyre told the court. Ms Murphy echoed her colleague's regrets, and said the midwives should have consulted another midwife or obstetrician at that moment. "I recognise that in this situation we made mistakes and I'm so remorseful about that," Ms Murphy said. "I know that Baby R suffered because of what we did, but I think that women can have a good experience and mostly do at home, even when they're having a vaginal birth after a caesarean." Later in the labour, Ms Murphy was taking a nap at 6:55pm when Ms Lapeyre first detected that Baby R's heart rate was abnormally fast. Ms Lapeyre did not wake Ms Murphy but told the coroner's court in hindsight, she should have. The inquest heard when the baby's heart rate was again found to be too fast 50 minutes later, Baby R's mother was taken to hospital. "I'm just sorry for the journey of grief you are undertaking and will be ongoing — I know about that journey," Ms Laperye said to Baby R's parents watching the inquest online. Ms Murphy told the inquest on Thursday she maintained Baby R's mother was "suitable to have the opportunity to try and have a home birth". She told the coroner's court she felt Baby R's mother was aware of the potential risks and was "diligent" in her preparation for birth. The inquest heard that in January 2022, eight months prior to Baby R's death, Bendigo Health head of obstetrics Nicola Yuen met with Ms Lapeyre and Ms Murphy with the aim of building a "collaborative relationship". "There were a couple of times Bendigo Health became aware of women birthing in the community who were high-risk," Dr Yuen said. Dr Yuen said while Ms Lapeyre was highly engaged with Bendigo Health after the meeting, the doctor did not recall the same attitude from Ms Murphy. Dr Yuen said there was a "missed opportunity" to change the outcome for Baby R, when the baby's mother declined a routine obstetrician consultation at 36 weeks' gestation. Ms Murphy had written to Bendigo Health saying Baby R's mother did "not need" the consultation, but hospital staff flagged risks in Baby R's mother's birth history and offered it anyway. Baby R's mother said in her statement to the inquest she declined the hospital's offer as she thought it was a "box ticking exercise". Ms Murphy told the court she regretted her wording in the letter and should have written that Baby R's mother did not "want" to see an obstetrician. However, the midwife said she did not think an obstetrician would have "positively contributed" to Baby R's mother's care. She said her previous clients had been "badgered and treated unkindly by obstetricians because of the choices they were making". Ms Lapeyre said women who chose home birth were rarely respected for their choices and obstetricians often used coercive language. But, she said she would tell her patients they needed to go into a home birth "with eyes wide open" and recommended they faced their fears of seeing an obstetrician. The court has heard since Ms Murphy and Ms Lapeyre were directed not to practice private midwifery by health authorities, more women in central Victoria had chosen to "free birth" without any healthcare professional present. The inquest continues.
Sydney Morning Herald
12 hours ago
- Sydney Morning Herald
NeuroScientific locks in deal to scale-up stem cell production
Perth-based stem cell therapy pioneer NeuroScientific Biopharmaceuticals has started transferring its patented StemSmart process to one of Australia's biggest and most experienced cell therapy manufacturers to scale up clinical-grade production. Queensland-based Q-Gen Cell Therapeutics will take over the manufacturing of StemSmart's specific mesenchymal stromal stem cells (MSC) from Royal Perth Hospital's Cell and Tissue Centre. NeuroScientific says the technology transfer will allow it to establish MSC manufacturing for its StemSmart infusions for further clinical trials and pursue commercial opportunities. The MSC technology was developed as a last-line infusion treatment for critically ill patients, including those experiencing severe immune complications from bone marrow transplants, kidney and lung transplant rejection and inflammatory Crohn's disease. 'This relationship will allow the company to scale the manufacturing of its StemSmart technology.' NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith NeuroScientific acquired the StemSmart technology in late June via its $4.1 million acquisition of unlisted Perth-based stem cell company Isopogen. Isopogen had previously signed a manufacturing contract with QIMR Berghofer, under which Q-Gen undertook manufacturing process development to scale up clinical-grade production of the StemSmart platform. Q-Gen, located in QIMR in Brisbane, has more than 25 years of experience in cell therapy manufacturing for industry. The laboratory specialises in manufacturing cellular immunotherapies for national and international clinical trials from 13 cleanrooms dedicated to cell manufacturing and quality control. NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith said: 'We are very pleased to be partnering with Q-Gen given their extensive experience in manufacturing, process development and GMP production of biologic products for clinical trials. This relationship will allow the company to scale the manufacturing of its StemSmart technology to address substantial market opportunities.' StemSmart offers a step up from traditional MSC manufacturing in that the cells are grown in a special medium, becoming activated in the process. The platform technology was developed at Royal Perth Hospital and manufactured using the hospital's processes.
The Age
12 hours ago
- The Age
NeuroScientific locks in deal to scale-up stem cell production
Perth-based stem cell therapy pioneer NeuroScientific Biopharmaceuticals has started transferring its patented StemSmart process to one of Australia's biggest and most experienced cell therapy manufacturers to scale up clinical-grade production. Queensland-based Q-Gen Cell Therapeutics will take over the manufacturing of StemSmart's specific mesenchymal stromal stem cells (MSC) from Royal Perth Hospital's Cell and Tissue Centre. NeuroScientific says the technology transfer will allow it to establish MSC manufacturing for its StemSmart infusions for further clinical trials and pursue commercial opportunities. The MSC technology was developed as a last-line infusion treatment for critically ill patients, including those experiencing severe immune complications from bone marrow transplants, kidney and lung transplant rejection and inflammatory Crohn's disease. 'This relationship will allow the company to scale the manufacturing of its StemSmart technology.' NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith NeuroScientific acquired the StemSmart technology in late June via its $4.1 million acquisition of unlisted Perth-based stem cell company Isopogen. Isopogen had previously signed a manufacturing contract with QIMR Berghofer, under which Q-Gen undertook manufacturing process development to scale up clinical-grade production of the StemSmart platform. Q-Gen, located in QIMR in Brisbane, has more than 25 years of experience in cell therapy manufacturing for industry. The laboratory specialises in manufacturing cellular immunotherapies for national and international clinical trials from 13 cleanrooms dedicated to cell manufacturing and quality control. NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith said: 'We are very pleased to be partnering with Q-Gen given their extensive experience in manufacturing, process development and GMP production of biologic products for clinical trials. This relationship will allow the company to scale the manufacturing of its StemSmart technology to address substantial market opportunities.' StemSmart offers a step up from traditional MSC manufacturing in that the cells are grown in a special medium, becoming activated in the process. The platform technology was developed at Royal Perth Hospital and manufactured using the hospital's processes.
